Comparison · NCT04478071-sae
Vadadustat vs Placebo: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Vadadustat vs Placebo: serious adverse events. Trial comparisons, record NCT04478071-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04478071-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.276 | 0.221 | 0.338 | wilson | |
| Risk in group 2 | 0.322 | 0.264 | 0.385 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0456 | -0.129 | 0.0392 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.858 | 0.645 | 1.14 | log | |
| Odds ratio, group 1 over group 2 | 0.804 | 0.536 | 1.21 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on Vadadustat than on Placebo | 21.9 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Vadadustat | vadadustat: Participants will receive vadadustat once daily for 14 days. | 61 | 221 | EG000 |
| Group 2 | Placebo | placebo: Participants will receive matching placebo once daily for 14 days. | 73 | 227 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- up to 28 days
Source ClinicalTrials.gov
Trial
- Title
- Vadadustat for the Prevention and Treatment of Acute Respiratory Distress Syndrome (ARDS) in Hospitalized Patients With Coronavirus Disease 2019 (COVID-19)
- NCT number
- NCT04478071
- Phases
- PHASE2
- Conditions
- Acute Respiratory Distress Syndrome, Coronavirus Infection
- Interventions
- vadadustat, placebo
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Results first posted
- 2025-03-26
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT04478071?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT04478071-sae